We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

97 hedge funds and large institutions have $314M invested in KalVista Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more call options, than puts

Call options by funds: $164K | Put options by funds: $138K

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

1.53% more ownership

Funds ownership: 95.67% → 97.2% (+1.5%)

8% less funds holding

Funds holding: 105 → 97 (-8)

23% less capital invested

Capital invested by funds: $408M → $314M (-$93.8M)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

Holders
97
Holders Change
-8
Holders Change %
-7.62%
% of All Funds
1.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
32
Reduced
28
Closed
23
Calls
$164K
Puts
$138K
Net Calls
+$26K
Net Calls Change
+$3.03M

Top Buyers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
+$18.3M
2
GPP
Great Point Partners
Connecticut
+$6.56M
3
LCM
Laurion Capital Management
New York
+$5.57M
4
SFM
Sphera Funds Management
Israel
+$5.03M
5
SCM
Suvretta Capital Management
New York
+$3.23M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$19.9M
2
DM
Deerfield Management
New York
-$15.7M
3
EAM
Eventide Asset Management
Massachusetts
-$8.39M
4
EA
Emerald Advisers
Pennsylvania
-$5.31M
5
NIP
Nicholas Investment Partners
California
-$3.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$1.84M -$8.39M -526,860 -79%
WP
27
Woodline Partners
California
$1.84M +$149K +9,387 +7%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$1.52M -$84.4K -5,300 -4%
ACM
29
Altium Capital Management
New York
$1.48M – – –
Goldman Sachs
30
Goldman Sachs
New York
$1.31M +$480K +30,136 +43%
Two Sigma Investments
31
Two Sigma Investments
New York
$1.29M -$399K -25,051 -20%
MP
32
Mangrove Partners
Connecticut
$1.22M +$1.46M +92,000 New
NFGH
33
Nan Fung Group Holdings
Hong Kong
$1.04M – – –
Bank of America
34
Bank of America
North Carolina
$891K +$861K +54,103 +408%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$870K -$119K -7,504 -10%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$849K +$407K +25,586 +66%
Morgan Stanley
37
Morgan Stanley
New York
$835K +$732K +45,963 +268%
N
38
Nuveen
North Carolina
$796K -$940K -59,022 -48%
Charles Schwab
39
Charles Schwab
California
$760K +$84.6K +5,317 +10%
Citigroup
40
Citigroup
New York
$716K +$400K +25,139 +87%
UBS Group
41
UBS Group
Switzerland
$708K +$324K +20,335 +61%
PVI
42
Pura Vida Investments
New York
$544K +$305K +19,139 +87%
BC
43
Birchview Capital
Vermont
$529K – – –
IC
44
Ikarian Capital
Texas
$484K -$955K -60,000 -62%
CL
45
CSS LLC
Illinois
$463K – – –
First Trust Advisors
46
First Trust Advisors
Illinois
$446K +$66.3K +4,166 +14%
TCM
47
Tekla Capital Management
Massachusetts
$418K -$1.09M -68,406 -68%
AC
48
Apogem Capital
New York
$407K +$170K +10,697 +53%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$402K -$166K -10,449 -26%
Barclays
50
Barclays
United Kingdom
$383K +$296K +18,582 +179%
1
2
3 4 5

KALV Hedge Fund Activity: Q4 2021 in Review

97 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2021, worth a combined $314M — down 23% from $408M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of KALV and 16 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 32 added.

The largest buyer was Frazier Management, adding an estimated $18.3M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $19.9M sold.

  • 97 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2021, down from 105 in Q3 2021.
  • Funds reported $314M of KalVista Pharmaceuticals stock for Q4 2021, down 23% quarter-over-quarter.
  • 16 funds opened new KalVista Pharmaceuticals positions in Q4 2021 and 23 closed out, a net change of -7 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2021 was Frazier Management, an estimated $18.3M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2021 was Janus Henderson Group, an estimated $19.9M sold.

Based on aggregated 13F filings for Q4 2021.